VCG
ALNY icon

Vantage Consulting Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vantage Consulting Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7
Closed -$1K – 165
2020
Q4 		$1K Buy
+7
New +$935 ﹤0.01% 1705

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vantage Consulting Group's ALNY Position: Q1 2021 in Review

Vantage Consulting Group sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2021, closing a stake of 7 shares — an estimated $1K sold.

Vantage Consulting Group first reported a position in ALNY in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 391 funds tracked by Wall St. Rank hold ALNY as of Q1 2021.

  • Vantage Consulting Group reported no remaining Alnylam Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 7 Alnylam Pharmaceuticals shares in Q1 2021, an estimated $1K.
  • Vantage Consulting Group first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Alnylam Pharmaceuticals position peaked at $1K in Q4 2020.
  • 391 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.